Publications by authors named "Nele Debackere"
Article Synopsis
- The study focuses on dosing patterns for GLP-1 receptor agonists, specifically dulaglutide and semaglutide, in treating Type 2 diabetes in France and Italy from August 2020 to December 2022.! -
- Over 600,000 patients were examined, revealing that most French patients started dulaglutide at 1.5 mg, while a significant portion of Italian patients began with semaglutide at various doses.! -
- Although dosing patterns were generally similar between the two countries, there were notable differences over time, highlighting the need for further real-world studies on GLP-1 RA utilization.!
Introduction: As new glucagon-like peptide 1 receptor agonist (GLP-1 RA) formulations are available, the aim of this study was to understand dulaglutide and subcutaneous (s.c.) semaglutide dosing patterns in people with type 2 diabetes mellitus (T2DM) in the UK and Germany as well as oral semaglutide in the UK.
View Article and Find Full Text PDF